Cross-sectional Study of Bone Density, Bone Microarchitecture, Vertebral Fractures and Trabecular Bone Score in Patients With Acromegaly Treated With Pegvisomant Compared to Patients With Untreated Active Acromegaly
Phase of Trial: Phase IV
Latest Information Update: 22 Feb 2019
Price : $35 *
At a glance
- Drugs Pegvisomant (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- 16 Feb 2019 Planned End Date changed from 30 Dec 2018 to 1 Mar 2020.
- 16 Feb 2019 Planned primary completion date changed from 30 Dec 2018 to 1 Mar 2020.
- 24 Jul 2017 New trial record